<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38673514</PMID><DateRevised><Year>2024</Year><Month>04</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Apr</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Organ-Dysfunction Markers in Mild-to-Moderate COVID-19 Convalescents.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2241</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm13082241</ELocationID><Abstract><AbstractText><b>Background</b>: A coronavirus disease 2019 (COVID-19) outbreak led to a worldwide pandemic. COVID-19 not only caused acute symptoms during the severe phase of the disease, but also induced long-term side effects on the functioning of many organs and systems. Symptoms that were associated with the disease and present at least 3 months after recovery were named long COVID. The aim of this study was to assess if mild-to-moderate COVID-19 may lead to the dysfunction of respiratory, cardiovascular, neural, and renal systems in healthy blood donors who recovered from the disease at least 6 months earlier. <b>Methods:</b> Here, we examined 294 adults among volunteer blood donors divided into convalescents (<i>n</i> = 215) and healthy controls (<i>n</i> = 79). Concentrations of soluble CD163, TGF beta, Lp-PLA2, NCAM-1, S100, NGAL, and creatinine were measured either by ELISA or automated methods. The probability value <i>p</i> &lt; 0.05 was considered as statistically significant. <b>Results:</b> We found significant differences in Lp-PLA2, S100, and NCAM-1 between convalescents and never-infected subjects. Lp-PLA2 and NCAM-1 were lower, and S100 higher, in convalescents than in the control group. <b>Conclusion:</b> Mild-to-moderate COVID-19 convalescents are at a low risk of developing lung fibrosis or chronic kidney disease. However, they should regularly carry out their prophylaxis examinations for early detection of possible negative outcomes of COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wi&#x15b;niewska</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Students Scientific Group of Laboratory Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kijak</LastName><ForeName>Aleksandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Students Scientific Group of Laboratory Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowak</LastName><ForeName>Karolina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Students Scientific Group of Laboratory Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lulek</LastName><ForeName>Michalina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Students Scientific Group of Laboratory Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Laboratory of Central Teaching Hospital, University Clinical Center of Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skwarek</LastName><ForeName>Agata</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Students Scientific Group of Laboratory Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma&#x142;ecka-Gie&#x142;dowska</LastName><ForeName>Milena</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5291-749X</Identifier><AffiliationInfo><Affiliation>Clinical Laboratory of Central Teaching Hospital, University Clinical Center of Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>&#x15a;miarowski</LastName><ForeName>Marcin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Students Scientific Group of Laboratory Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>W&#x105;sik</LastName><ForeName>Szczepan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Students Scientific Group of Laboratory Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciepiela</LastName><ForeName>Olga</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-3694-4076</Identifier><AffiliationInfo><Affiliation>Clinical Laboratory of Central Teaching Hospital, University Clinical Center of Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Medical University of Warsaw, 02-097 Warsaw, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">lung fibrosis</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">renal function</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>9</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>27</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>4</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38673514</ArticleId><ArticleId IdType="pmc">PMC11050795</ArticleId><ArticleId IdType="doi">10.3390/jcm13082241</ArticleId><ArticleId IdType="pii">jcm13082241</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Koz&#x142;owski P., Leszczy&#x144;ska A., Ciepiela O. Long COVID definition, symptoms, risk factors, epidemiology and autoimmunity&#x2014;A narrative review. Am. J. Med. Open. 2024 doi: 10.1016/j.ajmo.2024.100068. in press .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajmo.2024.100068</ArticleId></ArticleIdList></Reference><Reference><Citation>Guziejko K., Ta&#x142;ataj J., Czupryna P., Moniuszko-Malinowska A. Long COVID. Epidemiol. Rev. 2022;76:287&#x2013;295. doi: 10.32394/pe.76.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.32394/pe.76.27</ArticleId><ArticleId IdType="pubmed">36520039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G., Sanchis-Gomar F., Henry B.M. COVID-19 and its long-term sequelae: What do we know in 2023? Pol. Arch. Intern. Med. 2023;133:16402. doi: 10.20452/pamw.16402.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.16402</ArticleId><ArticleId IdType="pubmed">36626183</ArticleId></ArticleIdList></Reference><Reference><Citation>John A.E., Joseph C., Jenkins G., Tatler A.L. COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. Immunol. Rev. 2021;302:228&#x2013;240. doi: 10.1111/imr.12977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12977</ArticleId><ArticleId IdType="pmc">PMC8237078</ArticleId><ArticleId IdType="pubmed">34028807</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirawat R., Jain N., Aslam Saifi M., Rachamalla M., Godugu C. Lung fibrosis: Post-COVID-19 complications and evidences. Int. Immunopharmacol. 2023;116:109418. doi: 10.1016/j.intimp.2022.109418.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.109418</ArticleId><ArticleId IdType="pmc">PMC9633631</ArticleId><ArticleId IdType="pubmed">36736220</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohammadi A., Balan I., Yadav S., Matos W.F., Kharawala A., Gaddam M., Sarabia N., Koneru S.C., Suddapalli S.K., Marzban S. Post-COVID-19 Pulmonary Fibrosis. Cureus. 2022;14:e22770. doi: 10.7759/cureus.22770.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.22770</ArticleId><ArticleId IdType="pmc">PMC8974316</ArticleId><ArticleId IdType="pubmed">35371880</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqi H.K., Libby P., Ridker P.M. COVID-19&#x2014;A vascular disease. Trends Cardiovasc. Med. 2021;31:1&#x2013;5. doi: 10.1016/j.tcm.2020.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tcm.2020.10.005</ArticleId><ArticleId IdType="pmc">PMC7556303</ArticleId><ArticleId IdType="pubmed">33068723</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou A.G., Vrettou C.S., Keskinidou C., Dimopoulou I., Kotanidou A., Orfanos S.E. Endotheliopathy in Acute COVID-19 and Long COVID. Int. J. Mol. Sci. 2023;24:8237. doi: 10.3390/ijms24098237.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24098237</ArticleId><ArticleId IdType="pmc">PMC10179170</ArticleId><ArticleId IdType="pubmed">37175942</ArticleId></ArticleIdList></Reference><Reference><Citation>Tellis C.C., Tselepis A.D. Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) bound to LDL and HDL. Curr. Pharm. Des. 2014;20:6256&#x2013;6269. doi: 10.2174/1381612820666140622200916.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612820666140622200916</ArticleId><ArticleId IdType="pubmed">24953389</ArticleId></ArticleIdList></Reference><Reference><Citation>Dua P., Mishra A., Reeta K.H. Lp-PLA2 as a biomarker and its possible associations with SARS-CoV-2 infection. Biomark. Med. 2022;16:821&#x2013;832. doi: 10.2217/bmm-2021-1129.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/bmm-2021-1129</ArticleId><ArticleId IdType="pmc">PMC9196258</ArticleId><ArticleId IdType="pubmed">35694871</ArticleId></ArticleIdList></Reference><Reference><Citation>Monje M., Iwasaki A. The neurobiology of long COVID. Neuron. 2022;110:3484&#x2013;3496. doi: 10.1016/j.neuron.2022.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2022.10.006</ArticleId><ArticleId IdType="pmc">PMC9537254</ArticleId><ArticleId IdType="pubmed">36288726</ArticleId></ArticleIdList></Reference><Reference><Citation>Leng A., Shah M., Ahmad S.A., Premraj L., Wildi K., Li Bassi G., Pardo C.A., Choi A., Cho S.M. Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome and Potential Therapeutics. Cells. 2023;12:816. doi: 10.3390/cells12050816.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells12050816</ArticleId><ArticleId IdType="pmc">PMC10001044</ArticleId><ArticleId IdType="pubmed">36899952</ArticleId></ArticleIdList></Reference><Reference><Citation>Leone M.A., Helbok R., Bianchi E., Yasuda C.L., Konti M., Ramankulov D., Lolich M., Lovrencic-Huzjan A., Kovacs T., Armon C., et al. Outcome predictors of post-COVID conditions in the European Academy of Neurology COVID-19 registry. J. Neurol. 2024:1&#x2013;16. doi: 10.1007/s00415-024-12212-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-024-12212-8</ArticleId><ArticleId IdType="pubmed">38436682</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B., Xie Y., Xu E., Al-Aly Z. Kidney Outcomes in Long COVID. J. Am. Soc. Nephrol. 2021;32:2851&#x2013;2862. doi: 10.1681/ASN.2021060734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2021060734</ArticleId><ArticleId IdType="pmc">PMC8806085</ArticleId><ArticleId IdType="pubmed">34470828</ArticleId></ArticleIdList></Reference><Reference><Citation>Rai V. COVID-19 and Kidney: The Importance of Follow-Up and Long-Term Screening. Life. 2023;13:2137. doi: 10.3390/life13112137.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life13112137</ArticleId><ArticleId IdType="pmc">PMC10672056</ArticleId><ArticleId IdType="pubmed">38004277</ArticleId></ArticleIdList></Reference><Reference><Citation>Avotins L., Kroica J., Petersons A., Zentina D., Kravale Z., Saulite A., Racenis K. eGFR(cystatinC)/eGFR(creatinine) ratio &lt; 0.6 in patients with SARS-CoV-2 pneumonia: A prospective cohort study. BMC Nephrol. 2023;24:269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10500727</ArticleId><ArticleId IdType="pubmed">37704948</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergersen K.V., Pham K., Li J., Ulrich M.T., Merrill P., He Y., Alaama S., Qiu X., Harahap-Carrillo I.S., Ichii K., et al. Health disparities in COVID-19: Immune and vascular changes are linked to disease severity and persist in a high-risk population in Riverside County, California. BMC Public Health. 2023;23:1584. doi: 10.1186/s12889-023-16462-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-023-16462-5</ArticleId><ArticleId IdType="pmc">PMC10439554</ArticleId><ArticleId IdType="pubmed">37598150</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao C., Parimon T., Espindola M.S., Hohmann M.S., Konda B., Hogaboam C.M., Stripp B.R., Chen P. Maladaptive TGF-beta Signals to the Alveolar Epithelium Drive Fibrosis after COVID-19 Infection. Am. J. Respir. Crit. Care Med. 2023;208:201&#x2013;204. doi: 10.1164/rccm.202302-0264LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.202302-0264LE</ArticleId><ArticleId IdType="pmc">PMC10395488</ArticleId><ArticleId IdType="pubmed">37236627</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Martinez G., Jimenez-Alvarez L.A., Cruz-Lagunas A., Ignacio-Cortes S., Gomez-Garcia I.A., Rodriguez-Reyna T.S., Choreno-Parra J.A., Zuniga J. Possible Role of Matrix Metalloproteinases and TGF-beta in COVID-19 Severity and Sequelae. J. Interferon Cytokine Res. 2022;42:352&#x2013;368. doi: 10.1089/jir.2021.0222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2021.0222</ArticleId><ArticleId IdType="pmc">PMC9422783</ArticleId><ArticleId IdType="pubmed">35647937</ArticleId></ArticleIdList></Reference><Reference><Citation>Frischbutter S., Durek P., Witkowski M., Angermair S., Treskatsch S., Maurer M., Radbruch A., Mashreghi M.F. Serum TGF-beta as a predictive biomarker for severe disease and fatality of COVID-19. Eur. J. Immunol. 2023;53:e2350433. doi: 10.1002/eji.202350433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.202350433</ArticleId><ArticleId IdType="pubmed">37386908</ArticleId></ArticleIdList></Reference><Reference><Citation>Susak F., Vrsaljko N., Vince A., Papic N. TGF Beta as a Prognostic Biomarker of COVID-19 Severity in Patients with NAFLD-A Prospective Case-Control Study. Microorganisms. 2023;11:1571. doi: 10.3390/microorganisms11061571.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11061571</ArticleId><ArticleId IdType="pmc">PMC10303946</ArticleId><ArticleId IdType="pubmed">37375073</ArticleId></ArticleIdList></Reference><Reference><Citation>Zivancevic-Simonovic S., Minic R., Cupurdija V., Stanojevic-Pirkovic M., Milosevic-Djordjevic O., Jakovljevic V., Mihaljevic O. Transforming growth factor beta 1 (TGF-beta1) in COVID-19 patients: Relation to platelets and association with the disease outcome. Mol. Cell. Biochem. 2023;478:2461&#x2013;2471. doi: 10.1007/s11010-023-04674-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-023-04674-7</ArticleId><ArticleId IdType="pmc">PMC9984293</ArticleId><ArticleId IdType="pubmed">36869188</ArticleId></ArticleIdList></Reference><Reference><Citation>Sbierski-Kind J., Schlickeiser S., Feldmann S., Ober V., Gruner E., Pleimelding C., Gilberg L., Brand I., Weigl N., Ahmed M.I.M., et al. Persistent immune abnormalities discriminate post-COVID syndrome from convalescence. Infection. 2024:1&#x2013;11. doi: 10.1007/s15010-023-02164-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-023-02164-y</ArticleId><ArticleId IdType="pmc">PMC11142964</ArticleId><ArticleId IdType="pubmed">38326527</ArticleId></ArticleIdList></Reference><Reference><Citation>Volfovitch Y., Tsur A.M., Gurevitch M., Novick D., Rabinowitz R., Mandel M., Achiron A., Rubinstein M., Shoenfeld Y., Amital H. The intercorrelations between blood levels of ferritin, sCD163, and IL-18 in COVID-19 patients and their association to prognosis. Immunol. Res. 2022;70:817&#x2013;828. doi: 10.1007/s12026-022-09312-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-022-09312-w</ArticleId><ArticleId IdType="pmc">PMC9555272</ArticleId><ArticleId IdType="pubmed">36222965</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardelli M., Pierpaoli E., Marchegiani F., Marcheselli F., Piacenza F., Giacconi R., Recchioni R., Casoli T., Stripoli P., Provinciali M., et al. Biomarkers of cell damage, neutrophil and macrophage activation associated with in-hospital mortality in geriatric COVID-19 patients. Immun. Ageing. 2022;19:65. doi: 10.1186/s12979-022-00315-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-022-00315-7</ArticleId><ArticleId IdType="pmc">PMC9751505</ArticleId><ArticleId IdType="pubmed">36522763</ArticleId></ArticleIdList></Reference><Reference><Citation>Attia H., El Nagdy M., Halim R.M.A. Preliminary Study of sCD14 and sCD163 as Predictors of Disease Severity and ICU Admission in COVID-19: Relation to Hematological Parameters, Blood Morphological Changes and Inflammatory Biomarkers. Mediterr. J. Hematol. Infect. Dis. 2023;15:e2023046. doi: 10.4084/MJHID.2023.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.4084/MJHID.2023.046</ArticleId><ArticleId IdType="pmc">PMC10497305</ArticleId><ArticleId IdType="pubmed">37705527</ArticleId></ArticleIdList></Reference><Reference><Citation>Mostafa G.A., Ibrahim H.M., Al Sayed Shehab A., Gendy Y.G.E., Aly D.M.M., Shousha G.A.H. Up-regulated serum levels of soluble CD25 and soluble CD163 in pediatric patients with SARS-CoV-2. Eur. J. Pediatr. 2022;181:2299&#x2013;2309. doi: 10.1007/s00431-022-04398-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00431-022-04398-8</ArticleId><ArticleId IdType="pmc">PMC8888270</ArticleId><ArticleId IdType="pubmed">35233677</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J., Dean L.S., Jiyarom B., Gangcuangco L.M., Shah P., Awamura T., Ching L.L., Nerurkar V.R., Chow D.C., Igno F., et al. Elevated circulating monocytes and monocyte activation in COVID-19 convalescent individuals. Front. Immunol. 2023;14:1151780. doi: 10.3389/fimmu.2023.1151780.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1151780</ArticleId><ArticleId IdType="pmc">PMC10106598</ArticleId><ArticleId IdType="pubmed">37077911</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajamanickam A., Kumar N.P., Pandiarajan A.N., Selvaraj N., Munisankar S., Renji R.M., Venkatramani V., Murhekar M., Thangaraj J.W.V., Kumar M.S., et al. Dynamic alterations in monocyte numbers, subset frequencies and activation markers in acute and convalescent COVID-19 individuals. Sci. Rep. 2021;11:20254. doi: 10.1038/s41598-021-99705-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-99705-y</ArticleId><ArticleId IdType="pmc">PMC8511073</ArticleId><ArticleId IdType="pubmed">34642411</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu X.Y., Guo L., Wang Q., Yu X.B., Li L., Wei Q. Association between lipoprotein-associated phospholipase A(2) and lower extremity arterial disease in type 2 diabetes mellitus. Clin. Chim. Acta. 2020;510:228&#x2013;231. doi: 10.1016/j.cca.2020.07.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.07.023</ArticleId><ArticleId IdType="pubmed">32679127</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Jiang Y., Zhang Y., Li N., Yin Q., Liu L., Lv X., Liu Y., Li A., Fang B., et al. Abnormal upregulation of cardiovascular disease biomarker PLA2G7 induced by proinflammatory macrophages in COVID-19 patients. Sci. Rep. 2021;11:6811. doi: 10.1038/s41598-021-85848-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85848-5</ArticleId><ArticleId IdType="pmc">PMC7990942</ArticleId><ArticleId IdType="pubmed">33762651</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmo H.R.P., Yoshinaga M.Y., Castillo A.R., Britto Chaves-Filho A., Bonilha I., Barreto J., Muraro S.P., de Souza G.F., Davanzo G.G., Perroud M.W., Jr., et al. Phenotypic changes in low-density lipoprotein particles as markers of adverse clinical outcomes in COVID-19. Mol. Genet. Metab. 2023;138:107552. doi: 10.1016/j.ymgme.2023.107552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2023.107552</ArticleId><ArticleId IdType="pmc">PMC9969752</ArticleId><ArticleId IdType="pubmed">36889041</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravrand V., Mellot F., Ackermann F., Ballester M.C., Zuber B., Kirk J.T., Navalkar K., Yager T.D., Petit F., Pascreau T., et al. Stratification of COVID-19 Severity Using SeptiCyte RAPID, a Novel Host Immune Response Test. Viruses. 2023;15:419. doi: 10.3390/v15020419.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020419</ArticleId><ArticleId IdType="pmc">PMC9960895</ArticleId><ArticleId IdType="pubmed">36851633</ArticleId></ArticleIdList></Reference><Reference><Citation>Batsika C.S., Gerogiannopoulou A.D., Mantzourani C., Vasilakaki S., Kokotos G. The design and discovery of phospholipase A(2) inhibitors for the treatment of inflammatory diseases. Expert Opin. Drug Discov. 2021;16:1287&#x2013;1305. doi: 10.1080/17460441.2021.1942835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17460441.2021.1942835</ArticleId><ArticleId IdType="pubmed">34143707</ArticleId></ArticleIdList></Reference><Reference><Citation>Suto R., Pocsi M., Fagyas M., Kalina E., Fejes Z., Szentkereszty Z., Kappelmayer J., Nagy B., Jr. Comparison of Different Vascular Biomarkers for Predicting In-Hospital Mortality in Severe SARS-CoV-2 Infection. Microorganisms. 2024;12:229. doi: 10.3390/microorganisms12010229.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms12010229</ArticleId><ArticleId IdType="pmc">PMC10820061</ArticleId><ArticleId IdType="pubmed">38276214</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling Y., Tang S., Cao Y., Fu C. Relationship between Plasma Lipoprotein-Associated Phospholipase A2 Concentrations and Apolipoprotein in Stable Coronary Artery Disease Patients. Dis. Markers. 2020;2020:8818358. doi: 10.1155/2020/8818358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/8818358</ArticleId><ArticleId IdType="pmc">PMC7532362</ArticleId><ArticleId IdType="pubmed">33029257</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Acker H.H., Capsomidis A., Smits E.L., Van Tendeloo V.F. CD56 in the Immune System: More Than a Marker for Cytotoxicity? Front. Immunol. 2017;8:892. doi: 10.3389/fimmu.2017.00892.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00892</ArticleId><ArticleId IdType="pmc">PMC5522883</ArticleId><ArticleId IdType="pubmed">28791027</ArticleId></ArticleIdList></Reference><Reference><Citation>Laudanski K., Hajj J., Restrepo M., Siddiq K., Okeke T., Rader D.J. Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes. Biomedicines. 2021;9:1791. doi: 10.3390/biomedicines9121791.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9121791</ArticleId><ArticleId IdType="pmc">PMC8698659</ArticleId><ArticleId IdType="pubmed">34944606</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun B., Tang N., Peluso M.J., Iyer N.S., Torres L., Donatelli J.L., Munter S.E., Nixon C.C., Rutishauser R.L., Rodriguez-Barraquer I., et al. Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. Cells. 2021;10:386. doi: 10.3390/cells10020386.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells10020386</ArticleId><ArticleId IdType="pmc">PMC7918597</ArticleId><ArticleId IdType="pubmed">33668514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkstr&#xf6;m N.K., Strunz B., Ljunggren H.G. Natural killer cells in antiviral immunity. Nat. Rev. Immunol. 2022;22:112&#x2013;123. doi: 10.1038/s41577-021-00558-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00558-3</ArticleId><ArticleId IdType="pmc">PMC8194386</ArticleId><ArticleId IdType="pubmed">34117484</ArticleId></ArticleIdList></Reference><Reference><Citation>Saresella M., Trabattoni D., Marventano I., Piancone F., La Rosa F., Caronni A., Lax A., Bianchi L., Banfi P., Navarro J., et al. NK Cell Subpopulations and Receptor Expression in Recovering SARS-CoV-2 Infection. Mol. Neurobiol. 2021;58:6111&#x2013;6120. doi: 10.1007/s12035-021-02517-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-021-02517-4</ArticleId><ArticleId IdType="pmc">PMC8397607</ArticleId><ArticleId IdType="pubmed">34453271</ArticleId></ArticleIdList></Reference><Reference><Citation>Maucourant C., Filipovic I., Ponzetta A., Aleman S., Cornillet M., Hertwig L., Strunz B., Lentini A., Reinius B., Brownlie D., et al. Natural killer cell immunotypes related to COVID-19 disease severity. Sci. Immunol. 2020;5:eabd6832. doi: 10.1126/sciimmunol.abd6832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd6832</ArticleId><ArticleId IdType="pmc">PMC7665314</ArticleId><ArticleId IdType="pubmed">32826343</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao M., Liu Y., Yuan J., Wen Y., Xu G., Zhao J., Cheng L., Li J., Wang X., Wang F., et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 2020;26:842&#x2013;844. doi: 10.1038/s41591-020-0901-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId><ArticleId IdType="pubmed">32398875</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem G., Cheon S., Lee H., Choi S.J., Jeong S., Kim E.S., Jeong H.W., Jeong H., Park S.H., Kim Y.S., et al. Abnormality in the NK-cell population is prolonged in severe COVID-19 patients. J. Allergy Clin. Immunol. 2021;148:996&#x2013;1006.e18. doi: 10.1016/j.jaci.2021.07.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2021.07.022</ArticleId><ArticleId IdType="pmc">PMC8324384</ArticleId><ArticleId IdType="pubmed">34339730</ArticleId></ArticleIdList></Reference><Reference><Citation>Casado J.L., Moraga E., Vizcarra P., Velasco H., Martin-Hondarza A., Haemmerle J., Gomez S., Quereda C., Vallejo A. Expansion of CD56(dim)CD16(neg) NK Cell Subset and Increased Inhibitory KIRs in Hospitalized COVID-19 Patients. Viruses. 2021;14:46. doi: 10.3390/v14010046.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14010046</ArticleId><ArticleId IdType="pmc">PMC8780522</ArticleId><ArticleId IdType="pubmed">35062250</ArticleId></ArticleIdList></Reference><Reference><Citation>Aceti A., Margarucci L.M., Scaramucci E., Orsini M., Salerno G., Di Sante G., Gianfranceschi G., Di Liddo R., Valeriani F., Ria F., et al. Serum S100B protein as a marker of severity in COVID-19 patients. Sci. Rep. 2020;10:18665. doi: 10.1038/s41598-020-75618-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-75618-0</ArticleId><ArticleId IdType="pmc">PMC7596559</ArticleId><ArticleId IdType="pubmed">33122776</ArticleId></ArticleIdList></Reference><Reference><Citation>Mete E., Sabirli R., Goren T., Turkcuer I., Kurt O., Koseler A. Association Between S100b Levels and COVID-19 Pneumonia: A Case Control Study. In Vivo. 2021;35:2923&#x2013;2928. doi: 10.21873/invivo.12583.</Citation><ArticleIdList><ArticleId IdType="doi">10.21873/invivo.12583</ArticleId><ArticleId IdType="pmc">PMC8408717</ArticleId><ArticleId IdType="pubmed">34410988</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahin B.E., Celikbilek A., Kocak Y., Saltoglu G.T., Konar N.M., Hizmali L. Plasma biomarkers of brain injury in COVID-19 patients with neurological symptoms. J. Neurol. Sci. 2022;439:120324. doi: 10.1016/j.jns.2022.120324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2022.120324</ArticleId><ArticleId IdType="pmc">PMC9212259</ArticleId><ArticleId IdType="pubmed">35752131</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarraj J., Park E.S., Colpo G.D., Hinds S.N., Morales D., Ahnstedt H., Paz A.S., Assing A., Liu F., Juneja S., et al. Brain injury, endothelial injury and inflammatory markers are elevated and express sex-specific alterations after COVID-19. J. Neuroinflamm. 2021;18:277. doi: 10.1186/s12974-021-02323-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-021-02323-8</ArticleId><ArticleId IdType="pmc">PMC8627162</ArticleId><ArticleId IdType="pubmed">34838058</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Kido T., Shi J., McCafferty E., Ford J.M., Dal Bon K., Pulliam L. Blood Markers Show Neural Consequences of LongCOVID-19. Cells. 2024;13:478. doi: 10.3390/cells13060478.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells13060478</ArticleId><ArticleId IdType="pmc">PMC10969290</ArticleId><ArticleId IdType="pubmed">38534322</ArticleId></ArticleIdList></Reference><Reference><Citation>Menez S., Moledina D.G., Thiessen-Philbrook H., Wilson F.P., Obeid W., Simonov M., Yamamoto Y., Corona-Villalobos C.P., Chang C., Garibaldi B.T., et al. Prognostic Significance of Urinary Biomarkers in Patients Hospitalized With COVID-19. Am. J. Kidney Dis. 2022;79:257&#x2013;267.e1. doi: 10.1053/j.ajkd.2021.09.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2021.09.008</ArticleId><ArticleId IdType="pmc">PMC8542781</ArticleId><ArticleId IdType="pubmed">34710516</ArticleId></ArticleIdList></Reference><Reference><Citation>Pode Shakked N., de Oliveira M.H.S., Cheruiyot I., Benoit J.L., Plebani M., Lippi G., Benoit S.W., Henry B.M. Early prediction of COVID-19-associated acute kidney injury: Are serum NGAL and serum Cystatin C levels better than serum creatinine? Clin. Biochem. 2022;102:1&#x2013;8. doi: 10.1016/j.clinbiochem.2022.01.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinbiochem.2022.01.006</ArticleId><ArticleId IdType="pmc">PMC8801397</ArticleId><ArticleId IdType="pubmed">35093314</ArticleId></ArticleIdList></Reference><Reference><Citation>Serwin N., Cecerska-Heryc E., Pius-Sadowska E., Serwin K., Niedzwiedz A., Wisniewska M., Roszak M., Grygorcewicz B., Skwirczynska E., Machalinski B., et al. Renal and Inflammation Markers-Renalase, Cystatin C, and NGAL Levels in Asymptomatic and Symptomatic SARS-CoV-2 Infection in a One-Month Follow-Up Study. Diagnostics. 2022;12:108. doi: 10.3390/diagnostics12010108.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics12010108</ArticleId><ArticleId IdType="pmc">PMC8774569</ArticleId><ArticleId IdType="pubmed">35054276</ArticleId></ArticleIdList></Reference><Reference><Citation>Malinowska A., Heleniak Z., Muchlado M., Slizien Z., Ruszkowski J., Biedunkiewicz B., Tylicki L., Krol E., Debska-Slizien A. Changes in Kidney Graft Function in COVID-19 Convalescents. Transplant. Proc. 2022;54:884&#x2013;887. doi: 10.1016/j.transproceed.2022.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2022.03.003</ArticleId><ArticleId IdType="pmc">PMC8923994</ArticleId><ArticleId IdType="pubmed">35501173</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>